Windlas BiotechNSE:WINDLAS -3.07%91 Net Current Asset Value is ₹142.30 as of Mar. 2026, which is 100% below its 10-year median of 4.18. GuruFocus rates NSE:WINDLAS with a GF Score™ of 91/100 and a GF Value™ of ₹942.26 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 609 Drug Manufacturers companies, Windlas Biotech ranks worse than 51.89% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Windlas Biotech's net current asset value per share for the quarter that ended in Mar. 2026 was ₹142.30.
The historical rank and industry rank for Windlas Biotech's Net Current Asset Value or its related term are showing as below:
NSE:WINDLAS'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.6 Med: 4.18 Max: 8.06
Current: 5.79
During the past 8 years, the highest Price-to-Net-Current-Asset-Value Ratio of Windlas Biotech was 8.06. The lowest was 1.60. And the median was 4.18.
NSE:WINDLAS's Price-to-Net-Current-Asset-Value is ranked worse than 51.89% of 609
companies
in the Drug Manufacturers industry
Industry Median: 5.63
vs NSE:WINDLAS: 5.79
Windlas Biotech (NSE:WINDLAS) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Windlas Biotech Net Current Asset Value Related Terms
Windlas Biotech Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WINDLAS vs ZTS, UTHR: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ₹142.30 mean?
Windlas Biotech (NSE:WINDLAS) has a Net Current Asset Value of ₹142.30 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Windlas Biotech and its competitors. This is 3304% above median its historical median of 4.18. Over the past decade, Windlas Biotech's Net Current Asset Value has ranged from 1.60 to 8.06. According to the industry distribution chart, Windlas Biotech ranks #316 out of 609 companies in the Drug Manufacturers industry, placing it in the top 51.9%.
Is Windlas Biotech's Net Current Asset Value too high?
Windlas Biotech's current Net Current Asset Value of ₹142.30 is 3304% above median its 10-year median of 4.18. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 8.06. Based on the distribution chart, Windlas Biotech ranks #316 out of 609 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #316 out of 609 companies for Net Current Asset Value. This places Windlas Biotech in the lower half of its industry. The industry median Net Current Asset Value is 5.63. Historically, Windlas Biotech's own Net Current Asset Value has ranged from 1.60 to 8.06 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.63, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current Net Current Asset Value is ₹142.30, which is 3304% above median its own 10-year median of 4.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹942.26, compared to a current price of ₹827.70 — trading 12.2% below its estimated fair value. The current Net Current Asset Value is ₹142.30, which is 3304% above median its 10-year median of 4.18. Windlas Biotech's overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Net Current Asset Value is ₹142.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹827.70 is trading 12.2% below its estimated GF Value™ of ₹942.26.
GuruFocus considers Windlas Biotech to be Modestly Undervalued.
Key valuation signals for NSE:WINDLAS:
Net Current Asset Value: ₹142.30 (3304% above median its 10-year median of 4.18)
GF Value™: ₹942.26 vs. price of ₹827.70 (12.2% below fair value)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
91GF Score
Get the complete analysis for NSE:WINDLAS
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
